Free Trial

QuidelOrtho (QDEL) Stock Price, News & Analysis

-1.04 (-2.45%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.19 million shs
Average Volume
1.01 million shs
Market Capitalization
$2.77 billion
P/E Ratio
Dividend Yield
Price Target

QuidelOrtho MarketRank™ Stock Analysis

Analyst Rating
2.00 Rating Score
42.7% Upside
$59.00 Price Target
Short Interest
4.67% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.12mentions of QuidelOrtho in the last 14 days
Based on 14 Articles This Week
Insider Trading
Acquiring Shares
$99,652 Bought Last Quarter
Proj. Earnings Growth
From $2.09 to $3.48 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.61 out of 5 stars

Medical Sector

79th out of 921 stocks

Diagnostic Substances Industry

1st out of 13 stocks

QDEL stock logo

About QuidelOrtho Stock (NASDAQ:QDEL)

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

QDEL Stock Price History

QDEL Stock News Headlines

See More Headlines
Receive QDEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Diagnostic substances
Health Care Supplies
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$3.00 billion
Cash Flow
$10.63 per share
Book Value
$74.92 per share


Free Float
Market Cap
$2.77 billion

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Michael S. Iskra (Age 54)
    Interim CEO, Executive VP & Chief Commercial Officer
    Comp: $870.93k
  • Mr. Robert J. Bujarski J.D. (Age 55)
    Interim President, Executive VP & COO
    Comp: $961.26k
  • Mr. Joseph M. Busky CPA (Age 56)
    Chief Financial Officer
    Comp: $890.63k
  • Dr. Werner Kroll Ph.D. (Age 67)
    Senior Vice President of Research & Development
    Comp: $1.03M
  • Ms. Louise M. Brandy (Age 65)
    Chief Information Officer
  • Ruben Argueta
    Director of Investor Relations
  • Ms. Michelle A. Hodges J.D. (Age 61)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $1.8M
  • Mr. William J. FerenczyMr. William J. Ferenczy (Age 68)
    Point of Care Business Unit Leader
  • Ms. Tamara A. Ranalli (Age 51)
    Molecular Diagnostics Business Unit Leader

QDEL Stock Analysis - Frequently Asked Questions

Should I buy or sell QuidelOrtho stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" QDEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares.
View QDEL analyst ratings
or view top-rated stocks.

What is QuidelOrtho's stock price target for 2024?

7 brokers have issued 12 month price targets for QuidelOrtho's stock. Their QDEL share price targets range from $37.00 to $76.00. On average, they anticipate the company's share price to reach $59.00 in the next year. This suggests a possible upside of 42.7% from the stock's current price.
View analysts price targets for QDEL
or view top-rated stocks among Wall Street analysts.

How have QDEL shares performed in 2024?

QuidelOrtho's stock was trading at $73.70 at the beginning of 2024. Since then, QDEL shares have decreased by 43.9% and is now trading at $41.35.
View the best growth stocks for 2024 here

When is QuidelOrtho's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our QDEL earnings forecast

How were QuidelOrtho's earnings last quarter?

QuidelOrtho Co. (NASDAQ:QDEL) released its quarterly earnings data on Tuesday, February, 13th. The company reported $1.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.01 by $0.84. The business had revenue of $742.60 million for the quarter, compared to analyst estimates of $796.91 million. QuidelOrtho had a positive trailing twelve-month return on equity of 3.96% and a negative net margin of 61.65%. The firm's revenue was down 14.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.74 EPS.

What is Doug Bryant's approval rating as QuidelOrtho's CEO?

47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Doug Bryant has an approval rating of 76% among the company's employees.

What other stocks do shareholders of QuidelOrtho own?

Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM).

Who are QuidelOrtho's major shareholders?

QuidelOrtho's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.30%), LSV Asset Management (1.13%), Clearbridge Investments LLC (0.78%), Private Management Group Inc. (0.68%), Burgundy Asset Management Ltd. (0.35%) and Gagnon Securities LLC (0.33%). Insiders that own company stock include Joseph M Busky and Mary Lake Ph D Polan.
View institutional ownership trends

How do I buy shares of QuidelOrtho?

Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QDEL) was last updated on 5/22/2024 by Staff

From Our Partners